Otonomy Enrolls First Meniere's Disease Patients in OTO-104 Multiple-Dose Safety Study
October 9, 2014Otonomy enrolls the first patients in a multiple-dose safety study of their lead drug candidate, OTO-104, in patients with Ménière's disease in the U.K.
More »
Actavis to Acquire Durata Therapeutics, Inc.
October 6, 2014The definitive merger agreement under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock. Actavis expects the acquisition to be accretive by the end of the first year.
More »
FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia
October 3, 2014Durata Therapeutics announced it has received a Special Protocol Agreement (SPA) from the FDA on the design of its Phase 3 study DALVANCE for the treatment of patients with community-acquired pneumonia requiring intravenous therapy.
More »